RS59607B1 - Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan) - Google Patents

Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)

Info

Publication number
RS59607B1
RS59607B1 RS20191501A RSP20191501A RS59607B1 RS 59607 B1 RS59607 B1 RS 59607B1 RS 20191501 A RS20191501 A RS 20191501A RS P20191501 A RSP20191501 A RS P20191501A RS 59607 B1 RS59607 B1 RS 59607B1
Authority
RS
Serbia
Prior art keywords
irinotecan
peg
metronomic dosing
camptothecin prodrugs
camptothecin
Prior art date
Application number
RS20191501A
Other languages
English (en)
Inventor
Michael A Eldon
Shibani S Harite
Tamra L Barker
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of RS59607B1 publication Critical patent/RS59607B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
RS20191501A 2008-09-23 2009-09-23 Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan) RS59607B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US10693108P 2008-10-20 2008-10-20
US17343309P 2009-04-28 2009-04-28
EP09789364.8A EP2349346B1 (en) 2008-09-23 2009-09-23 Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Publications (1)

Publication Number Publication Date
RS59607B1 true RS59607B1 (sr) 2020-01-31

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20191501A RS59607B1 (sr) 2008-09-23 2009-09-23 Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)

Country Status (20)

Country Link
US (3) US8906353B2 (sr)
EP (1) EP2349346B1 (sr)
JP (3) JP2012503602A (sr)
KR (1) KR20110063457A (sr)
CN (1) CN102164617A (sr)
AU (1) AU2009297091B2 (sr)
CA (1) CA2736939C (sr)
CY (1) CY1122208T1 (sr)
DK (1) DK2349346T3 (sr)
ES (1) ES2744975T3 (sr)
HR (1) HRP20192120T1 (sr)
HU (1) HUE047352T2 (sr)
IL (1) IL211888A (sr)
LT (1) LT2349346T (sr)
MX (1) MX2011003063A (sr)
PL (1) PL2349346T3 (sr)
PT (1) PT2349346T (sr)
RS (1) RS59607B1 (sr)
SI (1) SI2349346T1 (sr)
WO (1) WO2010036335A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047352T2 (hu) 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)
CN109608436B (zh) * 2011-04-08 2022-10-11 斯法尔制药私人有限公司 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法
MX366911B (es) * 2012-11-28 2019-07-30 Nektar Therapeutics Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de topoisomerasa i de acción prolongada.
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
US10835548B2 (en) 2016-06-02 2020-11-17 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
WO2020061007A1 (en) * 2018-09-17 2020-03-26 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
EP1683520B1 (en) 1996-03-12 2013-11-20 PG-TXL Company, L.P. Water-soluble prodrugs
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
EP1259562B1 (en) 1999-12-22 2006-02-15 Nektar Therapeutics Al, Corporation Sterically hindered derivatives of water soluble polymers
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
AU2001280679A1 (en) 2000-07-21 2002-02-05 Prad Research And Development N.V. Nuclear magnetic resonance methods for extracting information about a fluid in arock
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
MXPA04004026A (es) 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
KR20050042013A (ko) 2001-10-30 2005-05-04 넥타르 테라퓨틱스 에이엘, 코포레이션 레티노산의 수용성 중합체 콘쥬게이트
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
JP2005529938A (ja) 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
CN102172405B (zh) * 2003-09-17 2014-11-12 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
JP5596924B2 (ja) * 2006-02-17 2014-09-24 カスケード プロドラッグ インコーポレイテッド ビンカアルカロイドn酸化物および類似体による過剰増殖疾患の処置
BRPI0807232A2 (pt) 2007-02-09 2014-04-29 Enzon Pharmaceuticals Inc Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina
CN101199857B (zh) * 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
HUE047352T2 (hu) 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)

Also Published As

Publication number Publication date
IL211888A0 (en) 2011-06-30
US10525051B2 (en) 2020-01-07
JP2016216510A (ja) 2016-12-22
JP2012503602A (ja) 2012-02-09
US9801873B2 (en) 2017-10-31
MX2011003063A (es) 2011-04-21
ES2744975T3 (es) 2020-02-27
CN102164617A (zh) 2011-08-24
JP6076317B2 (ja) 2017-02-08
KR20110063457A (ko) 2011-06-10
US20180028525A1 (en) 2018-02-01
US20150087668A1 (en) 2015-03-26
CA2736939A1 (en) 2010-04-01
SI2349346T1 (sl) 2019-12-31
US20110269789A1 (en) 2011-11-03
US8906353B2 (en) 2014-12-09
PL2349346T3 (pl) 2020-03-31
AU2009297091B2 (en) 2015-03-05
CA2736939C (en) 2021-09-14
AU2009297091A1 (en) 2010-04-01
PT2349346T (pt) 2019-10-24
EP2349346A1 (en) 2011-08-03
CY1122208T1 (el) 2020-11-25
JP2015034180A (ja) 2015-02-19
HUE047352T2 (hu) 2020-04-28
DK2349346T3 (da) 2019-10-07
IL211888A (en) 2015-08-31
WO2010036335A1 (en) 2010-04-01
EP2349346B1 (en) 2019-08-28
HRP20192120T1 (hr) 2020-02-21
LT2349346T (lt) 2019-09-25

Similar Documents

Publication Publication Date Title
AP3408A (en) Tobacco curing method
GB0822893D0 (en) Advanced speed profiles - Further updates
EP2291348A4 (en) WATER-SOLUBLE ACETAMINOPHENANALOGA
PL2488561T3 (pl) Polibutadieny katalizowane neodymem
PT2349346T (pt) Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano).
GB2462829B (en) Measurement method
GB0803107D0 (en) Method
EP2336393A4 (en) GALVANOPLASTY PROCESS
GB0810418D0 (en) Method
ZA201009263B (en) Plant regulatory sequences
EP2458378A4 (en) METHOD FOR MEASURING THE INSULIN LEVEL
GB0807410D0 (en) Method
GB0804981D0 (en) Method
EP2309852A4 (en) NOVEL PROCEDURE
EP2239093A4 (en) PRODUCTION INSTALLATION
GB0809404D0 (en) Method
EP2275814A4 (en) A-BETA-Oligomer-MEASURING METHOD
EP2321435A4 (en) WIEDERAUFKOHLUNGSVERFAHREN
EP2301991A4 (en) PROCESS FOR PRODUCING POLYSILANE
GB0805862D0 (en) Method
AU326445S (en) Meter
GB0806186D0 (en) Method
GB0810116D0 (en) Method
GB0804242D0 (en) Clopidogrel solution
GB0812957D0 (en) Quwb-it (game)